Education
About Us
Working with TipRanks
Follow Us
Jade Biosciences (JBIO)
NASDAQ:JBIO
Total Valuation
Jade Biosciences has a market cap or net worth of $736.07M. The enterprise value is $420.13M.
Market Cap$736.07M
Enterprise Value$420.13M
Share Statistics
Jade Biosciences has 46,004,204 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,004,204
Owned by Insiders12.79%
Owned by Institutions44.33%
Financial Efficiency
Jade Biosciences’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -96.98%.
Return on Equity (ROE)-0.91
Return on Assets (ROA)-0.87
Return on Invested Capital (ROIC)-96.98%
Return on Capital Employed (ROCE)-0.98
Revenue Per Employee0.00
Profits Per Employee-1.39M
Employee Count50
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Jade Biosciences is ―. Jade Biosciences’s PEG ratio is 0.07.
PE Ratio―
PS Ratio0.00
PB Ratio0.99
Price to Fair Value0.99
Price to FCF-1.06
Price to Operating Cash Flow-19.55
PEG Ratio0.07
Income Statement
In the last 12 months, Jade Biosciences had revenue of 0.00 and earned -69.63M in profits. Earnings per share was -85.26.
Revenue0.00
Gross Profit-282.00K
Operating Income-74.60M
Pretax Income-69.57M
Net Income-69.63M
EBITDA-69.29M
Earnings Per Share (EPS)-85.26
Cash Flow
In the last 12 months, operating cash flow was -69.71M and capital expenditures -193.00K, giving a free cash flow of -69.90M billion.
Operating Cash Flow-69.71M
Free Cash Flow-69.90M
Free Cash Flow per Share-1.52
Dividends & Yields
Jade Biosciences pays an annual dividend of $2.4, resulting in a dividend yield of 14.68%
Dividend Per Share$2.4
Dividend Yield14.68%
Payout Ratio-17.61%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.11
52-Week Price Change70.21%
50-Day Moving Average14.64
200-Day Moving Average10.19
Relative Strength Index (RSI)54.98
Average Volume (3m)127.19K
Important Dates
Jade Biosciences upcoming earnings date is May 18, 2026, Before Open (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Jade Biosciences as a current ratio of 20.93, with Debt / Equity ratio of 0.42%
Current Ratio20.93
Quick Ratio20.93
Debt to Market Cap<0.01
Net Debt to EBITDA0.48
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Jade Biosciences has paid 55.00K in taxes.
Income Tax55.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Jade Biosciences EV to EBITDA ratio is -0.61, with an EV/FCF ratio of -0.60.
EV to Sales0.00
EV to EBITDA-0.61
EV to Free Cash Flow-0.60
EV to Operating Cash Flow-0.60
Balance Sheet
Jade Biosciences has $198.91M in cash and marketable securities with $747.00K in debt, giving a net cash position of $198.16M billion.
Cash & Marketable Securities$198.91M
Total Debt$747.00K
Net Cash$198.16M
Net Cash Per Share$4.31
Tangible Book Value Per Share$93.60
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Jade Biosciences is $22.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.33
Price Target Upside39.56% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast89.16%